Skip to content
drillr.ai

BCDA

BioCardia, Inc.

NASDAQ · USHealthcareBiotechnology
$0.90+9.57%

Price as of Jul 20, 2026

BCDA news

BioCardia, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026

    SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia(®), Inc. (https://www.globenewswire.com/Tracker?data=8GiDy3uLZOFLkUJ-mJderv52N5cVs_Ljk2bEdrzhGaU3H3KcVd2X4KuZqE5fkQZ1HQgpKjX7GHH9bl6zasTy-h47lpyLd96fgOxIP0S5QMc=) [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the first quarter of 2026 by conference call on Friday, Ma

    Globe Newswire ·

  2. BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure

    SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia(®), Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug Administration (FDA) of the CardiAMP HF clinical study data and on its plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP(®) System for ischemic chronic heart failure with reduced ejection fraction (

    Globe Newswire ·

  3. BioCardia Reports 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (https://www.globenewswire.com/Tracker?data=6RAj97khnVvlySLJ0Polz7b-naQHgyBqQaUT2lo-a3Eqbbwfei4wQ-YFHY_nIFvZ9xSPHJTE1U6DJU83AF9WmYI3v8P8xI7cCPmdYGh7ZfQ=) [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2025 and filed its annual report on Form 10-K with the Securities and Exchang

    Globe Newswire ·

  4. BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

    SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (https://www.globenewswire.com/Tracker?data=c62NH9mXsAktByrGGmRQS0D1n9Jqz2tHr9VD3DoqPgl-6_gdzcu38w8FMwAhoLmtPB7daVSsUdMZ_diYuu_mYL7WXx1oBSPYN2Xu47IJQI0=) [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tue

    Globe Newswire ·

  5. BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA

    SUNNYVALE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- BioCardia(®), Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for the approval of its Helix Transendocardial Delivery Catheter (“Helix”) intended for intramyocardial therapeutic and diagnostic agent delivery. BioCardia has had preliminary meetings with both FDA Center for Devices and Radiologic

    Globe Newswire ·